Japan Grants Priority Review For Chugai's Herceptin For Gastric Cancer
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare granted priority review for Herceptin (trastuzumab) for HER2-positive advanced or recurrent gastric cancer